Efficacy of Chemotherapy Following Prior PARP-Inhibitor Treatment in Patients with Ovarian Cancer
In the subsequent chemotherapy of recurrent ovarian cancer after platinum-based chemotherapy and PARPi, the gemcitabine+carboplatin regimen demonstrated a potential to delay recurrence more effectively compared to other therapies.
Authors
- Junsik Park (ORCID: https://orcid.org/0000-0003-4094-2097)
- Eun Ji Nam (ORCID: https://orcid.org/0000-0003-0189-3560)
- Se Ik Kim (ORCID: https://orcid.org/0000-0002-9790-6735)
- Sang Wun Kim (ORCID: https://orcid.org/0000-0002-8342-8701)
- Sung-Hoon Kim
- Jae‐Weon Kim (ORCID: https://orcid.org/0000-0003-1835-9436)
- Byoung‐Gie Kim (ORCID: https://orcid.org/0000-0002-0572-8450)
- Jung Chul Kim (ORCID: https://orcid.org/0000-0002-0720-0991)
- Young Tae Kim (ORCID: https://orcid.org/0000-0002-7347-1052)
- Yong Jae Lee (ORCID: https://orcid.org/0000-0003-0297-3116)
- Jung-Yun Lee
Institutions
- Seoul National University (KR)
- Yonsei University (KR)
- Soonchunhyang University (KR)
- Samsung Medical Center (KR)
- Bucheon University (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2025-03-19
- DOI
- https://doi.org/10.4143/crt.2024.1202
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00